Background Growth-differentiation factor-15(GDF-15)is a promising prognostic biomarker in patients with chronic heart failure (CHF).Comparatively little is known about the value of repeated measurement of GDF-15with C...Background Growth-differentiation factor-15(GDF-15)is a promising prognostic biomarker in patients with chronic heart failure (CHF).Comparatively little is known about the value of repeated measurement of GDF-15with CI-IF in Chinese Han population.This study sought to identify the clinical value of repeated measurement of GDF-15in Chinese Han patients with post-myocardial infarction CHF. Methods In total,232consecutive Chinese Hart patients with post-myocardial infarction CHF were enrolled prospectively from January 2014to June 2016.The plasma concentration of GDF-15was determined on admission and over 12months.Patients were followed up for all-cause death and a composite outcome of major adverse cardiac events (MACE)included all-cause death,myocardial infarction and first heart failure (HF)re-hospitalization.Association with other clinical variables and adverse outcomes of repeated measurement of GDF-15 was explored.Results The median baseline GDF-15level was 2025ng/L.Baseline GDF-15was moderately associated with baseline N-terminal pro-B type nalriuretic peptide (NT-proBNP)(coefficient 0.561,P <0.001).During a median follow-up of 20months,there were 53deaths and 100MACE.GDF-I5remained an independent predictor of all-cause death (adjusted hazard ratio 1.826per 1Ln U,95%CI: 1.037-8.360;P =0.037)and MACE (adjusted hazard ratio 2.243per I Ln U,95%CI:1.181-1.775;P <0.001)adjusted for established risk factors.Repeated measurement of GDF-15was performed in 173survivals over 12months.Increase of GDF-15over 12months was associ- ated with dilatation of left ventricle and acted as an independent predictor of subsequent all-canse death (adjusted HR =3.164,95%CI: 1.245~.041;P =0.015).In the joint model,GDF-15was also shown to be a risk factor for all-cause death (HR =2.749,95%CI: 1.667-3.831;P <0.001)and MACE (FIR =2.434,95%CI:1.425-3.443;P <0.001).Conclusions Repeated measurements of GDF-15 have promising prognostic value of the risk of all-cause death in Chinese Han patients with CI-IF post-myocardial infarction.GDF-15may展开更多
目的探讨ICU机械通气患者竖脊肌横截面积丢失量(ESMcsa Loss)与血清生长分化因子-15(GDF-15)的相关性,以及它们对ICU获得性肌无力(ICU-AW)的诊断价值和60 d生存状态的预测价值。方法选择2018年6月至2019年11月本院ICU收治的行有创机械...目的探讨ICU机械通气患者竖脊肌横截面积丢失量(ESMcsa Loss)与血清生长分化因子-15(GDF-15)的相关性,以及它们对ICU获得性肌无力(ICU-AW)的诊断价值和60 d生存状态的预测价值。方法选择2018年6月至2019年11月本院ICU收治的行有创机械通气治疗的急性呼吸衰竭患者,分别在第1天及第7天ELISA法测定血清GDF-15浓度,通过CT影像勾画并计算胸12水平左右竖脊肌总横截面积。采用英国医学研究委员会肌力评定法(MRC-score)进行肌力评分。根据患者入ICU第7天MRC-score评分将患者分为ICU-AW组和非ICU-AW组,比较并分析两组患者分别在入ICU第1天及第7天血清GDF-15、ESMcsa及MRC-score差异。分析患者第7天血清GDF-15、ESMcsa Loss、MRC-score相关性。采用受试者工作特征曲线(ROC)计算患者第7天血清GDF-15、ESMcsa Loss及竖脊肌横截面积丢失率(ESMcsa Loss Ratio)对机械通气患者ICU-AW诊断预测价值。绘制患者生存曲线图,评估GDF-15及ESMcsa Loss Ratio对患者60 d生存状态预测价值。结果最终入选92例患者,根据第7天MRC-score<48分,诊断ICU-AW组49例,非ICU-AW组43例。ICU-AW组机械通气时间,ICU住院时间及医院住院时间高于非ICU-AW组,其他基线指标差异均无统计学意义。治疗第1天,两组患者血清GDF-15、ESMcsa及MRC-score差异无统计学意义;ICUAW组第7天GDF-15浓度明显高于非ICU-AW组,ESMcsa、MRC-score显著低于非ICU-AW组[GDF-15(pg/mL):2529.53±625.67比1614.21±567.18;ESMcsa(cm2):23.76±6.85比29.15±6.51;MRC-score(分):41.10±3.35比51.23±2.84,均P<0.001]。ESMcsa Loss及ESMcsa Loss Ratio与第7天血清GDF-15水平呈显著正相关(r分别0.2355和0.3192),ESMcsa Loss及ESMcsa Loss Ratio与MRC-score评分呈显著负相关(r分别-0.3072和-0.3527)。ROC曲线分析显示,第7天血清GDF-15、ESMcsa Loss及ESMcsa Loss Ratio对机械通气患者ICU-AW均有预测价值[ROC曲线下面积(AUC)分别为0.904,0.835和0.889,均P<0.001]。绘制患者60 d生存曲线图�展开更多
文摘Background Growth-differentiation factor-15(GDF-15)is a promising prognostic biomarker in patients with chronic heart failure (CHF).Comparatively little is known about the value of repeated measurement of GDF-15with CI-IF in Chinese Han population.This study sought to identify the clinical value of repeated measurement of GDF-15in Chinese Han patients with post-myocardial infarction CHF. Methods In total,232consecutive Chinese Hart patients with post-myocardial infarction CHF were enrolled prospectively from January 2014to June 2016.The plasma concentration of GDF-15was determined on admission and over 12months.Patients were followed up for all-cause death and a composite outcome of major adverse cardiac events (MACE)included all-cause death,myocardial infarction and first heart failure (HF)re-hospitalization.Association with other clinical variables and adverse outcomes of repeated measurement of GDF-15 was explored.Results The median baseline GDF-15level was 2025ng/L.Baseline GDF-15was moderately associated with baseline N-terminal pro-B type nalriuretic peptide (NT-proBNP)(coefficient 0.561,P <0.001).During a median follow-up of 20months,there were 53deaths and 100MACE.GDF-I5remained an independent predictor of all-cause death (adjusted hazard ratio 1.826per 1Ln U,95%CI: 1.037-8.360;P =0.037)and MACE (adjusted hazard ratio 2.243per I Ln U,95%CI:1.181-1.775;P <0.001)adjusted for established risk factors.Repeated measurement of GDF-15was performed in 173survivals over 12months.Increase of GDF-15over 12months was associ- ated with dilatation of left ventricle and acted as an independent predictor of subsequent all-canse death (adjusted HR =3.164,95%CI: 1.245~.041;P =0.015).In the joint model,GDF-15was also shown to be a risk factor for all-cause death (HR =2.749,95%CI: 1.667-3.831;P <0.001)and MACE (FIR =2.434,95%CI:1.425-3.443;P <0.001).Conclusions Repeated measurements of GDF-15 have promising prognostic value of the risk of all-cause death in Chinese Han patients with CI-IF post-myocardial infarction.GDF-15may
文摘目的探讨ICU机械通气患者竖脊肌横截面积丢失量(ESMcsa Loss)与血清生长分化因子-15(GDF-15)的相关性,以及它们对ICU获得性肌无力(ICU-AW)的诊断价值和60 d生存状态的预测价值。方法选择2018年6月至2019年11月本院ICU收治的行有创机械通气治疗的急性呼吸衰竭患者,分别在第1天及第7天ELISA法测定血清GDF-15浓度,通过CT影像勾画并计算胸12水平左右竖脊肌总横截面积。采用英国医学研究委员会肌力评定法(MRC-score)进行肌力评分。根据患者入ICU第7天MRC-score评分将患者分为ICU-AW组和非ICU-AW组,比较并分析两组患者分别在入ICU第1天及第7天血清GDF-15、ESMcsa及MRC-score差异。分析患者第7天血清GDF-15、ESMcsa Loss、MRC-score相关性。采用受试者工作特征曲线(ROC)计算患者第7天血清GDF-15、ESMcsa Loss及竖脊肌横截面积丢失率(ESMcsa Loss Ratio)对机械通气患者ICU-AW诊断预测价值。绘制患者生存曲线图,评估GDF-15及ESMcsa Loss Ratio对患者60 d生存状态预测价值。结果最终入选92例患者,根据第7天MRC-score<48分,诊断ICU-AW组49例,非ICU-AW组43例。ICU-AW组机械通气时间,ICU住院时间及医院住院时间高于非ICU-AW组,其他基线指标差异均无统计学意义。治疗第1天,两组患者血清GDF-15、ESMcsa及MRC-score差异无统计学意义;ICUAW组第7天GDF-15浓度明显高于非ICU-AW组,ESMcsa、MRC-score显著低于非ICU-AW组[GDF-15(pg/mL):2529.53±625.67比1614.21±567.18;ESMcsa(cm2):23.76±6.85比29.15±6.51;MRC-score(分):41.10±3.35比51.23±2.84,均P<0.001]。ESMcsa Loss及ESMcsa Loss Ratio与第7天血清GDF-15水平呈显著正相关(r分别0.2355和0.3192),ESMcsa Loss及ESMcsa Loss Ratio与MRC-score评分呈显著负相关(r分别-0.3072和-0.3527)。ROC曲线分析显示,第7天血清GDF-15、ESMcsa Loss及ESMcsa Loss Ratio对机械通气患者ICU-AW均有预测价值[ROC曲线下面积(AUC)分别为0.904,0.835和0.889,均P<0.001]。绘制患者60 d生存曲线图�
